Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$57.67
-2.0%		$55.97
$33.76
▼
$61.14
$14.38B0.472.59 million shs103,089 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$37.58
-2.3%		$32.96
$23.62
▼
$40.17
$23.62B0.812.09 million shs629,034 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$79.20
-2.7%		$97.29
$63.23
▼
$130.00
$5.17B0.61847,381 shs62,287 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$530.91
-1.0%		$510.46
$409.07
▼
$609.35
$22.80B0.49540,299 shs17,386 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.79%+0.82%-0.27%+3.10%+46.79%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+10.73%+8.82%+14.52%+31.87%+14.66%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-1.81%-7.42%-19.30%-36.54%+11.62%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.98%+10.47%+10.01%-4.84%+18.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$57.67
-2.0%		$55.97
$33.76
▼
$61.14
$14.38B0.472.59 million shs103,089 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$37.58
-2.3%		$32.96
$23.62
▼
$40.17
$23.62B0.812.09 million shs629,034 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$79.20
-2.7%		$97.29
$63.23
▼
$130.00
$5.17B0.61847,381 shs62,287 shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$530.91
-1.0%		$510.46
$409.07
▼
$609.35
$22.80B0.49540,299 shs17,386 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
+0.79%+0.82%-0.27%+3.10%+46.79%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+10.73%+8.82%+14.52%+31.87%+14.66%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-1.81%-7.42%-19.30%-36.54%+11.62%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
-0.98%+10.47%+10.01%-4.84%+18.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.29-12.80% Downside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$40.838.65% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$142.5680.01% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.71
Moderate Buy$621.0016.97% Upside

Current Analyst Ratings Breakdown

Latest MIRM, GMAB, UTHR, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $54.00
10/1/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/29/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$123.00 ➝ $130.00
9/28/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$144.00
9/28/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$145.00 ➝ $160.00
9/28/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$140.00 ➝ $195.00
9/24/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral ➝ Sell$321.00
9/24/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral ➝ Sell$321.00
9/14/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
9/14/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
9/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B5.87$2.99 per share19.29$8.06 per share7.15
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$4.13B5.68$1.74 per share21.59$9.10 per share4.13
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$618.07M8.32$0.05 per share1,626.74$6.12 per share12.94
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B7.15$32.33 per share16.42$164.81 per share3.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.2515.501.7435.33%42.17%31.76%11/3/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2729.8023.941.8919.08%14.89%7.73%11/5/2026 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$14.55N/AN/AN/A-139.18%-36.28%-8.54%11/3/2026 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$27.9519.0217.902.7241.56%20.18%17.98%11/4/2026 (Estimated)

Latest MIRM, GMAB, UTHR, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8780N/AN/AN/A$647.90 millionN/A
11/3/2026Q3 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.53N/AN/AN/A$178.06 millionN/A
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
8/5/2026Q2 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.86$7.27+$0.41$7.27$804.65 million$783.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.86
2.74
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.73
5.41

Institutional Ownership

CompanyInstitutional Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
43364.93 million59.53 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.89 million39.20 millionOptionable

Recent News About These Companies

Connect Biopharma (NASDAQ:CNTB) vs. United Therapeutics (NASDAQ:UTHR) Financial Analysis
October 4 at 2:46 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083914
United Therapeutics (NASDAQ:UTHR) Stock Falls 4.1% After Insider Selling
October 4 at 1:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083624
Top Medical Stocks To Consider - September 30th
October 3 at 6:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083182
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock
October 3 at 5:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082815
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), United Therapeutics (UTHR) and NervGen Pharma (NGEN)
October 3 at 1:34 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MLTX/pressreleases/4934076/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-united-therapeutics-uthr-and-nervgen-pharma-ngen/
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-martine-rothblatt-sells-9500-shares-of-stock-2026-10-02/
United Therapeutics (NASDAQ:UTHR) Shares Down 4.1% on Insider Selling
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-united-therapeutics-nasdaq-uthr-shares-down-41-on-insider-selling-2026-10-02/
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR)
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NBIX/pressreleases/4925877/analysts-have-conflicting-sentiments-on-these-healthcare-companies-tango-therapeutics-tngx-neurocrine-nbix-and-united-therapeutics-uthr/
United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares
October 2, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-10-02/
United Therapeutics (NASDAQ:UTHR) CEO Sells $3,926,212.60 in Stock
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-392621260-in-stock-2026-10-01/
Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,689,085.00 in Stock
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-evp-sells-468908500-in-stock-2026-10-01/
United Therapeutics Prevails In Patent Litigation Against Liquidia
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695556/united-therapeutics-prevails-in-patent-litigation-against-liquidia.aspx
United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle
October 1, 2026  |  barchart.comhttps://www.barchart.com/story/news/4916627/united-therapeutics-just-sent-liquidia-stock-lower-after-patent-battle
Why United Therapeutics (UTHR) Stock Is Up Today
October 1, 2026  |  quiverquant.comQ
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999089/uthr-prevails-in-lqda-s-yutrepia-patent-dispute-stock-up-nearly-13?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2999089
Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute
October 1, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62113623/liquidia-stock-extends-slide-following-us-court-ruling-in-patent-dispute
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
October 1, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/upgrades/26/10/62113057/this-united-therapeutics-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday?utm_source=snapi
United Therapeutics Won Its Patent War and Liquidia Collapsed
October 1, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/united-therapeutics-won-its-patent-war-and-liquidia-collapsed/
United Therapeutics Won Its Patent War and Liquidia Collapsed
October 1, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/united-therapeutics-won-its-patent-war-and-liquidia-collapsed/?utm_source=snapi
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia
October 1, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62103103/united-therapeutics-stock-rises-following-federal-court-patent-victory-over-liquidia
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More
October 1, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/here-are-thursdays-top-wall-street-analyst-research-calls-bp-dollar-tree-exxon-mobil-lennar-occidental-petroleum-rocket-lab-teva-pharmaceuticals-united-therapeutics-and-more/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Exelixis stock logo

Exelixis NASDAQ:EXEL

$57.67 -1.18 (-2.01%)
As of 10:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$37.58 -0.90 (-2.33%)
As of 10:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$79.19 -2.24 (-2.74%)
As of 10:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$530.91 -5.49 (-1.02%)
As of 10:09 AM Eastern
This is a fair market value price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas